COMP vs PECO

Compass, Inc. exhibits significant fundamental weakness, highlighted by a Piotroski F-Score of 3/9, placing it in the 'Weak' health category. While the company maintains strong top-line revenue growth of 23.10% and a low Price/Sales ratio of 0.84, these are offset by negative profit margins, a negative ROE of -9.79%, and a concerning liquidity position with a current ratio of 0.86. There is a stark disconnect between the bullish analyst target price of $13.25 and the internal reality of consistent earnings misses (0/4 beats in the last year) and aggressive insider selling by the CFO and General Counsel.

PECO exhibits a stable but mediocre Piotroski F-Score of 4/9, while trading at a significant premium to both its Graham Number ($19.08) and Intrinsic Value ($26.25). The most critical concern is the unsustainable dividend payout ratio of 140.81%, indicating the company is paying out more than it earns. Despite strong 5-year historical price performance and a 'Buy' analyst consensus, the combination of a bearish technical trend (10/100) and extreme valuation multiples suggests a high risk of correction.